Author Affiliation: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
Two human papillomavirus (HPV) L1 viruslike particle (VLP) vaccines have been developed against HPV types 16 and 18—the 2 HPV types that account for about 70% of cervical cancers worldwide.1 Both vaccines have been found to have high prophylactic efficacy in large clinical trials.2-6
Markowitz LE. HPV Vaccines—Prophylactic, Not Therapeutic. JAMA. 2007;298(7):805–806. doi:10.1001/jama.298.7.805
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: